Supervised exercise after oesophageal cancer surgery: the PERFECT multicentre randomized clinical trial
- PMID: 33837380
- PMCID: PMC10364897
- DOI: 10.1093/bjs/znab078
Supervised exercise after oesophageal cancer surgery: the PERFECT multicentre randomized clinical trial
Abstract
Background: This study investigated whether a supervised exercise programme improves quality of life (QoL), fatigue and cardiorespiratory fitness in patients in the first year after oesophagectomy.
Methods: The multicentre PERFECT trial randomly assigned patients to an exercise intervention (EX) or usual care (UC) group. EX patients participated in a 12-week moderate- to high-intensity aerobic and resistance exercise programme supervised by a physiotherapist. Primary (global QoL, QoL summary score) and secondary (QoL subscales, fatigue and cardiorespiratory fitness) outcomes were assessed at baseline, 12 and 24 weeks and analysed as between-group differences using either linear mixed effects models or ANCOVA.
Results: A total of 120 patients (mean(s.d.) age 64(8) years) were included and randomized to EX (61 patients) or UC (59 patients). Patients in the EX group participated in 96 per cent (i.q.r. 92-100 per cent) of the exercise sessions and the relative exercise dose intensity was high (92 per cent). At 12 weeks, beneficial EX effects were found for QoL summary score (3.5, 95 per cent c.i. 0.2 to 6.8) and QoL role functioning (9.4, 95 per cent c.i. 1.3 to 17.5). Global QoL was not statistically significant different between groups (3.0, 95 per cent c.i. -2.2 to 8.2). Physical fatigue was lower in the EX group (-1.2, 95 per cent c.i. -2.6 to 0.1), albeit not significantly. There was statistically significant improvement in cardiorespiratory fitness following EX compared with UC (peak oxygen uptake (1.8 ml/min/kg, 95 per cent c.i. 0.6 to 3.0)). After 24 weeks, all EX effects were attenuated.
Conclusions: A supervised exercise programme improved cardiorespiratory fitness and aspects of QoL.
Trial registration: Dutch Trial Register NTR 5045 (www.trialregister.nl/trial/4942).
© The Author(s) 2021. Published by Oxford University Press on behalf of BJS Society Ltd.
Figures



References
-
- Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL. et al.; CROSS study group. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer [CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015;16:1090–1098 - PubMed
-
- Gottlieb-Vedi E, Kauppila JH, Malietzis G, Nilsson M, Markar SR, Lagergren J.. Long-term survival in esophageal cancer after minimally invasive compared to open esophagectomy: a systematic review and meta-analysis. Ann Surg 2019;270:1005–1017 - PubMed
-
- Schandl A, Lagergren J, Johar A, Lagergren P.. Health-related quality of life 10 years after oesophageal cancer surgery. Eur J Cancer 2016;69:43–50 - PubMed
-
- Noordman BJ, Verdam MGE, Lagarde SM, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI. et al. Effect of neoadjuvant chemoradiotherapy on health-related quality of life in esophageal or junctional cancer: results from the randomized CROSS trial. J Clin Oncol 2018;36:268–275 - PubMed
-
- Noordman BJ, Verdam MGE, Lagarde SM, Shapiro J, Hulshof MCCM, van Berge Henegouwen MI. et al. Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the randomized CROSS trial. Ann Oncol 2018;29:445–451 - PubMed